Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, Datroway and US FDA
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
FDA bans red dye 3
FDA bans red food dye due to potential cancer risk
The U.S. Food and Drug Administration has officially banned red dye — called Red 3, or Erythrosine — from foods, dietary supplements and ingested medicines, as reported on Wednesday.
FDA bans red food dye with cancer links
Manufacturers will have at least two years to phase the carcinogenic additive Red Dye No. 3 out of their products.
FDA Bans Red No. 3 from Food and Drinks, Citing Cancer Risks
The artificial food dye can be found in candy, beverages, chips and other packaged foods — often consumed by children.
2d
on MSN
FDA moves to ban Red 3, citing concern over cancer in some animals
FDA officials have telegraphed the decision for months. While the agency has long said that it did not think evidence of Red ...
Healio
14h
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
phillyvoice.com
9h
The FDA wants to limit nicotine in cigarettes — a move that could save millions of lives
Temple pulmonologist Dr. Jamie Garfield says the proposed regulation is an effective harm reduction strategy, but suggests it ...
3d
on MSN
To combat chronic diseases, FDA proposes putting nutrition labels on front of packages
The proposed "Nutrition info box" would show customers whether products have low, medium or high levels of saturated fat, sodium and added sugars.
4d
AbbVie secures option to license Simcere's blood cancer drug candidate
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
4d
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback